Zymeworks Inc. (ZYME) stands out in the targeted oncology therapeutics sector with its proprietary Azymetric® platform and a promising pipeline of bispecific antibodies. Despite current financial challenges, a 12-month price...
Pharvaris N.V. emerges as a promising player in the hereditary angioedema market with its first-in-class oral treatment, deucrictibant. With a "Buy" rating and a 12-month price target of $42.00, the...
GE Vernova stands at the forefront of energy transformation, offering a tantalising investment opportunity. Leveraging a robust portfolio in gas power, renewables, and grid modernisation, the company anticipates a 20%...
The semiconductor industry is no stranger to cyclical challenges, but Intel Corporation (INTC) has recently made headlines with a significant workforce reduction of over 5,500 employees in July 2025, marking...
HUTCHMED (China) Limited offers an intriguing investment opportunity in the burgeoning targeted oncology and immunology sector. With a robust pipeline and strategic international partnerships, the potential for growth is promising...
ACM Research, Inc. (ACMR) provides a promising investment opportunity, strategically positioned to benefit from China's burgeoning semiconductor industry. With strong technological advantages like SAPS and TEBO, and steady revenue growth,...
Eve Holding, Inc. (NYSE: EVEX) offers an intriguing yet speculative play in the burgeoning urban air mobility market. Despite the uncertainties associated with its pre-revenue stage and technological hurdles, the...
Key Takeaways Alphabet’s valuation metrics, including a price-to-earnings (P/E) ratio of 20x, are significantly lower than most of its Magnificent Seven peers, positioning it as a potential outlier. The valuation...
Nokia Corporation, amidst its prowess in 5G infrastructure and a robust patent portfolio, faces challenges in licensing and margin pressure. Our analysis leads to a "Hold" rating with a €4.80...
Discover the intriguing potential of Merus N.V., a clinical-stage biotech firm making waves with its Bispecific antibody platform, Biclonics®. With petosemtamab showing promising Phase 2 results in cancer treatment and...
